JOP20190182B1 - أسيتاميد n-] 4-فلور-5-]] (4s,2s)-2-ميثيل-4-](5-ميثيل-1،2،4-اوكسادايزول-3-يل)ميثوكسي[-1-بيبيرديل[ميثيل[ ثيازول-2-يل[ كمثبط oga - Google Patents

أسيتاميد n-] 4-فلور-5-]] (4s,2s)-2-ميثيل-4-](5-ميثيل-1،2،4-اوكسادايزول-3-يل)ميثوكسي[-1-بيبيرديل[ميثيل[ ثيازول-2-يل[ كمثبط oga

Info

Publication number
JOP20190182B1
JOP20190182B1 JOP/2019/0182A JOP20190182A JOP20190182B1 JO P20190182 B1 JOP20190182 B1 JO P20190182B1 JO P20190182 A JOP20190182 A JO P20190182A JO P20190182 B1 JOP20190182 B1 JO P20190182B1
Authority
JO
Jordan
Prior art keywords
methyl
oxadiazol
thiazol
piperidyl
acetamide
Prior art date
Application number
JOP/2019/0182A
Other languages
English (en)
Inventor
Nicolas Jacques Francois Dreyfus
Peter James Lindsay-Scott
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of JOP20190182A1 publication Critical patent/JOP20190182A1/ar
Application granted granted Critical
Publication of JOP20190182B1 publication Critical patent/JOP20190182B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يوفر الاختراع الحالي مركب له الصيغة I: الصيغة I أو ملح مقبول صيدليًا مما سبق، واستخدام مركبات لها الصيغة I لعلاج أمراض تنكسية عصبية واضطرابات، مثل مرض آلزهايمر.
JOP/2019/0182A 2017-01-27 2018-01-19 أسيتاميد n-] 4-فلور-5-]] (4s,2s)-2-ميثيل-4-](5-ميثيل-1،2،4-اوكسادايزول-3-يل)ميثوكسي[-1-بيبيرديل[ميثيل[ ثيازول-2-يل[ كمثبط oga JOP20190182B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762451137P 2017-01-27 2017-01-27
PCT/US2018/014331 WO2018140299A1 (en) 2017-01-27 2018-01-19 N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor

Publications (2)

Publication Number Publication Date
JOP20190182A1 JOP20190182A1 (ar) 2019-07-25
JOP20190182B1 true JOP20190182B1 (ar) 2023-03-28

Family

ID=61157343

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0182A JOP20190182B1 (ar) 2017-01-27 2018-01-19 أسيتاميد n-] 4-فلور-5-]] (4s,2s)-2-ميثيل-4-](5-ميثيل-1،2،4-اوكسادايزول-3-يل)ميثوكسي[-1-بيبيرديل[ميثيل[ ثيازول-2-يل[ كمثبط oga

Country Status (37)

Country Link
US (1) US10081625B2 (ar)
EP (1) EP3573983B1 (ar)
JP (1) JP6738970B2 (ar)
KR (1) KR102275338B1 (ar)
CN (1) CN110198940B (ar)
AR (1) AR110747A1 (ar)
AU (1) AU2018213029B2 (ar)
BR (1) BR112019013535A2 (ar)
CA (1) CA3049141C (ar)
CL (1) CL2019001978A1 (ar)
CO (1) CO2019007711A2 (ar)
CR (1) CR20190320A (ar)
CY (1) CY1124257T1 (ar)
DK (1) DK3573983T3 (ar)
DO (1) DOP2019000187A (ar)
EA (1) EA038368B1 (ar)
EC (1) ECSP19053616A (ar)
ES (1) ES2871949T3 (ar)
HR (1) HRP20211011T1 (ar)
HU (1) HUE054990T2 (ar)
IL (1) IL267693B (ar)
JO (1) JOP20190182B1 (ar)
LT (1) LT3573983T (ar)
MA (1) MA47368B1 (ar)
MD (1) MD3573983T2 (ar)
MX (1) MX2019008846A (ar)
MY (1) MY197494A (ar)
PE (1) PE20191406A1 (ar)
PH (1) PH12019501707A1 (ar)
PL (1) PL3573983T3 (ar)
PT (1) PT3573983T (ar)
RS (1) RS61979B1 (ar)
SI (1) SI3573983T1 (ar)
TW (1) TWI654978B (ar)
UA (1) UA123472C2 (ar)
WO (1) WO2018140299A1 (ar)
ZA (1) ZA201904171B (ar)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017003658B1 (pt) 2014-08-28 2022-12-06 Asceneuron Sa Composto, mistura, método para inibição de uma glicosidase, e, composição farmacêutica
MA43677A (fr) 2016-02-25 2018-11-28 Asceneuron Sa Inhibiteurs de glycosidases
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
CN109071526B (zh) 2016-02-25 2023-02-28 阿森纽荣股份公司 哌嗪衍生物的酸加成盐
AU2017222964B2 (en) 2016-02-25 2020-01-02 Asceneuron S. A. Glycosidase inhibitors
TWI669302B (zh) 2017-05-25 2019-08-21 美商美國禮來大藥廠 5-甲基-1,3,4-<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 ed10999.png" img-content="tif" orientation="portrait" inline="yes" giffile="ed10999.png"></img>二唑-2-基化合物
WO2019037860A1 (en) 2017-08-24 2019-02-28 Asceneuron S.A. LINEAR INHIBITORS OF GLYCOSIDASE
TWI726329B (zh) 2018-06-22 2021-05-01 美商美國禮來大藥廠 2,3-二氫呋喃并[2,3-b]吡啶化合物
WO2020028115A1 (en) * 2018-07-31 2020-02-06 Eli Lilly And Company 5-methyl-4-fluoro-thiazol-2-yl compounds
EP3829634A1 (en) 2018-07-31 2021-06-09 Eli Lilly and Company Combination therapy
US11731972B2 (en) 2018-08-22 2023-08-22 Asceneuron Sa Spiro compounds as glycosidase inhibitors
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
BR112021004739A2 (pt) 2018-09-19 2021-06-01 Biogen Ma Inc. inibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidase
TWI716107B (zh) 2018-09-26 2021-01-11 美商美國禮來大藥廠 6-氟-2-甲基苯并[d]噻唑-5-基化合物
JP2022510430A (ja) 2018-12-05 2022-01-26 バイオジェン・エムエイ・インコーポレイテッド モルホリニル、ピペラジニル、オキサゼパニル及びジアゼパニルｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤
AR117989A1 (es) * 2019-02-04 2021-09-08 Biogen Ma Inc Inhibidores de o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa de éter bicíclico
WO2021094312A1 (en) 2019-11-11 2021-05-20 Janssen Pharmaceutica Nv Pyrrolidine and bicycloheteroaryl containing oga inhibitor compounds
WO2021110656A1 (en) 2019-12-02 2021-06-10 Janssen Pharmaceutica Nv Oga inhibitor compounds
IL293931A (en) 2019-12-18 2022-08-01 Janssen Pharmaceutica Nv oga inhibitor compounds
CA3160367A1 (en) 2019-12-18 2021-06-24 Jose Manuel Bartolome-Nebreda Oga inhibitor compounds
WO2021123291A1 (en) 2019-12-18 2021-06-24 Janssen Pharmaceutica Nv Oga inhibitor compounds
AR123031A1 (es) 2020-07-23 2022-10-26 Lilly Co Eli Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo
US20230286972A1 (en) 2020-08-03 2023-09-14 Biogen Ma Inc. Crystaline forms of an o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitor
WO2023070064A1 (en) 2021-10-22 2023-04-27 Eli Lilly And Company O-glcnacase (oga) inhibitor combination therapy
WO2023150483A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease
WO2024083820A1 (en) 2022-10-18 2024-04-25 Institut National de la Santé et de la Recherche Médicale Method and composition for determining the level of o-glcnacylation in horses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8726763D0 (en) 1987-11-16 1987-12-23 Fujisawa Pharmaceutical Co Thiazole compounds
ES2388547T3 (es) 2003-04-18 2012-10-16 Eli Lilly And Company Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas de 5-HT 1F
SE0302116D0 (sv) 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
KR20080087833A (ko) * 2005-12-21 2008-10-01 쉐링 코포레이션 히스타민 ｈ３ 길항제로서 유용한 페녹시피페리딘 및 이의유사체
WO2008121257A1 (en) * 2007-03-28 2008-10-09 Merck & Co., Inc. Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators
TWI431004B (zh) * 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
US9120781B2 (en) 2010-05-11 2015-09-01 Simon Fraser University Selective glycosidase inhibitors and uses thereof
AU2014241065B2 (en) * 2013-03-14 2017-08-31 Merck Patent Gmbh Glycosidase inhibitors
US9732065B2 (en) * 2013-05-30 2017-08-15 Sumitomo Dainippon Pharma Co., Ltd. Cyclic aminomethyl pyrimidine derivative
BR112017003658B1 (pt) * 2014-08-28 2022-12-06 Asceneuron Sa Composto, mistura, método para inibição de uma glicosidase, e, composição farmacêutica
WO2017106254A1 (en) 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
US20200079766A1 (en) * 2016-12-16 2020-03-12 Janssen Pharmaceutica Nv Monocyclic oga inhibitor compounds

Also Published As

Publication number Publication date
ES2871949T3 (es) 2021-11-02
PL3573983T3 (pl) 2021-10-04
IL267693A (en) 2019-08-29
BR112019013535A2 (pt) 2020-01-07
AR110747A1 (es) 2019-05-02
HUE054990T2 (hu) 2021-10-28
IL267693B (en) 2021-08-31
CA3049141C (en) 2021-02-16
US20180215751A1 (en) 2018-08-02
EA201991515A1 (ru) 2020-01-16
NZ754849A (en) 2021-10-29
PH12019501707A1 (en) 2020-03-16
CN110198940A (zh) 2019-09-03
PE20191406A1 (es) 2019-10-04
DK3573983T3 (da) 2021-06-28
CR20190320A (es) 2019-08-27
MX2019008846A (es) 2019-09-10
JP6738970B2 (ja) 2020-08-12
RS61979B1 (sr) 2021-07-30
TWI654978B (zh) 2019-04-01
EA038368B1 (ru) 2021-08-17
HRP20211011T1 (hr) 2021-09-17
DOP2019000187A (es) 2019-08-15
CN110198940B (zh) 2022-09-23
CY1124257T1 (el) 2022-07-22
JOP20190182A1 (ar) 2019-07-25
ECSP19053616A (es) 2019-08-30
TW201836607A (zh) 2018-10-16
MD3573983T2 (ro) 2021-10-31
SI3573983T1 (sl) 2021-08-31
KR20190096421A (ko) 2019-08-19
KR102275338B1 (ko) 2021-07-12
AU2018213029B2 (en) 2020-11-05
WO2018140299A1 (en) 2018-08-02
CA3049141A1 (en) 2018-08-02
CL2019001978A1 (es) 2019-12-13
EP3573983A1 (en) 2019-12-04
PT3573983T (pt) 2021-06-17
JP2020504142A (ja) 2020-02-06
UA123472C2 (uk) 2021-04-07
AU2018213029A1 (en) 2019-07-04
EP3573983B1 (en) 2021-04-21
US10081625B2 (en) 2018-09-25
CO2019007711A2 (es) 2019-07-31
MA47368B1 (fr) 2021-07-29
MY197494A (en) 2023-06-19
ZA201904171B (en) 2022-01-26
LT3573983T (lt) 2021-07-26

Similar Documents

Publication Publication Date Title
JOP20190182B1 (ar) أسيتاميد n-] 4-فلور-5-]] (4s,2s)-2-ميثيل-4-](5-ميثيل-1،2،4-اوكسادايزول-3-يل)ميثوكسي[-1-بيبيرديل[ميثيل[ ثيازول-2-يل[ كمثبط oga
AR111693A1 (es) Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
EA202190681A1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
NZ712207A (en) Tetrahydropyrrolothiazine compounds
CL2008001868A1 (es) Compuestos derivados de n-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas; composicion farmaceutica que comprende a dicho compuesto; y uso para el tratamiento de enfermedades inflamatorias del intestino, enfermedad alergica
MA55560A (fr) Dérivés d&#39;amide n-hétéroaromatiques destinés au traitement du cancer
EA201790305A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE
JOP20200059A1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
EA202190686A1 (ru) 5-7-членные гетероциклические амиды в качестве ингибиторов jak
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
PH12019500568A1 (en) Dopamine-b-hydroxylase inhibitors
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
TN2016000491A1 (en) Carboxamide derivatives.
PH12020551297A1 (en) Compounds having s1p5 receptor agonistic activity
EA201892687A1 (ru) Кристаллическая форма соединения, подавляющего активность протеинкиназы, и её применение
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
TN2017000448A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer&#39;s disease
EA202190359A1 (ru) Способы лечения нейродегенеративных расстройств
EA201891447A1 (ru) Кристаллическая форма 1,3-тиазол-5-илметил-[(2r,5r)-5-{[(2s)-2-[(метил-{[2-(пропан-2-ил)-1,3-тиазол-4-ил]метил}карбамоил)-мино]-4-(морфолин-4-ил)бутаноил-9-амино}-1,6-дифенилгексан-2-ил]карбамата или кобицистата
EA202190452A1 (ru) Ингибиторы cdk8/19
MA40345B1 (fr) Nouvelle forme polymorphe de chlorhydrate de n-[2-(6-fluoro-1h-indol-3-yl)éthyl]-3-(2,2,3,3-tétrafluoropropoxy) benzylamine pour le de traitement de la maladie d&#39;alzheimer
TH1901004570A (th) N-[4-ฟลูออโร-5-[[(2s,4s)-2-เมธิล-4-[(5-เมธิล-1,2,4-ออกซะไดอะซอล-3-อิล)เมธอกซิ]-1-พิเพอริดิล]เมธิล]ไธอะซอล-2-อิล]แอซิแทมีดในการเป็นสารยับยั้งoga
EA202090241A1 (ru) Новые гетероциклические соединения как ингибиторы cdk8/19
MX2020009334A (es) Compuestos para tratar la enfermedad de alzheimer.